Display Settings:

Format

Send to:

Choose Destination

    Virol J. 2008 Jul 9;5:78.

    Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

    Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ.

    Molecular Virology Diagnostic & Research Laboratory, Department of Medicine, Clinical Sciences Building, Cork University Hospital, Cork, Ireland. i.moreau@ucc.ie

    Pre-treatment HCV quasispecies complexity and diversity may predict response to interferon based anti-viral therapy. The objective of this study was to retrospectively (1) examine temporal changes in quasispecies prior to the start of therapy and (2) investigate extensively quasispecies evolution in a group of 10 chronically infected patients with genotype 3a, treated with pegylated alpha2a-Interferon and ribavirin. The degree of sequence heterogeneity within the hypervariable region 1 was assessed by analyzing 20-30 individual clones in serial serum samples. Genetic parameters, including amino acid Shannon entropy, Hamming distance and genetic distance were calculated for each sample. Treatment outcome was divided into (1) sustained virological responders (SVR) and (2) treatment failure (TF). Our results indicate, (1) quasispecies complexity and diversity are lower in the SVR group, (2) quasispecies vary temporally and (3) genetic heterogeneity at baseline can be use to predict treatment outcome. We discuss the results from the perspective of replicative homeostasis.

    PMID: 18613968 [PubMed - indexed for MEDLINE]

    PMCID: PMC2483966

    Publication Types, MeSH Terms, Substances, Secondary Source ID

    Publication Types:

    MeSH Terms:

    Substances:

    Secondary Source ID:

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Ribavirin (Copegus®, Rebetol®)

      Ribavirin is used with another medication called an interferon to treat hepatitis C. Ribavirin is in a class of antiviral medications called nucleoside analogues. It works by stopping the virus that causes hepatitis C fr...

    • Peginterferon alfa-2a (Pegasys®)

      Peginterferon alfa-2a is used alone or in combination with ribavirin (a medication) to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage an...